NCT06120244 Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
| NCT ID | NCT06120244 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Condition | Healthy |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2033-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2023-11-01 with a primary completion date of 2033-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Infections in the lower respiratory tract (lungs) are the leading cause of death from infectious disease worldwide. This was true even before the COVID-19 pandemic. Respiratory viruses are still a major health threat. Many of these viruses infect people by penetrating the thin skin that lines the nose. These viruses can also spread easily to other people when they multiply in the tissues that line the nose. Researchers want to learn more about what these viruses do inside the nose, how they get from the nose to the lungs, and how they spread from person to person. Objective: To collect cell samples from inside the noses of healthy people. These cells will be stored for use in future research on respiratory diseases. Eligibility: Healthy volunteers aged 18 years and older. Design: Most participants will have 1 visit on 1 day. They will be asked questions. Those who have a runny nose, coughing, congestion, or fever will be asked to wait up to 21 days before participating. Participants will be given a slender swab with small bristles at the end. They will rub the inside of their nose with the swab. A clinic staff member will be present to help, if needed. Participants will provide their name, age, and sex. This information will be encoded so that only certain researchers will know the participants identities. Participants will not be contacted again....
Eligibility Criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Aged \>=18 years. * Able to provide informed consent. * Willing to allow biological samples and data to be stored for future research. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * History of respiratory symptoms including but not limited to runny nose, coughing, congestion, and/or fever within the past 14 days. * NIH and laboratory staff with direct involvement in the operation or maintenance of the repository are excluded from participation. * An individual who has any condition that, in the judgment of the investigator, may put them at undue risk or make them unsuitable for participation in the study will be excluded.
Contact & Investigator
Emmie de Wit, Ph.D.
PRINCIPAL INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Frequently Asked Questions
Who can join the NCT06120244 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06120244 currently recruiting?
Yes, NCT06120244 is actively recruiting participants. Contact the research team at emmie.dewit@nih.gov for enrollment information.
Where is the NCT06120244 trial being conducted?
This trial is being conducted at Hamilton, United States.
Who is sponsoring the NCT06120244 clinical trial?
NCT06120244 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Emmie de Wit, Ph.D. at National Institute of Allergy and Infectious Diseases (NIAID). The trial plans to enroll 120 participants.